IE910597A1 - Peptides which inhibit blood coagulation, processes for the preparation thereof and the use thereof - Google Patents

Peptides which inhibit blood coagulation, processes for the preparation thereof and the use thereof

Info

Publication number
IE910597A1
IE910597A1 IE059791A IE59791A IE910597A1 IE 910597 A1 IE910597 A1 IE 910597A1 IE 059791 A IE059791 A IE 059791A IE 59791 A IE59791 A IE 59791A IE 910597 A1 IE910597 A1 IE 910597A1
Authority
IE
Ireland
Prior art keywords
glu
phe
asp
pro
peptide
Prior art date
Application number
IE059791A
Other versions
IE66493B1 (en
Inventor
Werner Stueber
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of IE910597A1 publication Critical patent/IE910597A1/en
Publication of IE66493B1 publication Critical patent/IE66493B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Peptides of the formula I A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15 in which A1 is hydrogen, cysteine, acetylcysteine, one or two alkyl groups with 1-4 C atoms, an acyl group with 2-10 C atoms, an acyl group with 2-10 C atoms and another carboxyl group, or a protective group customary in peptide chemistry, A2 is a bond, Asn, Asp, Gln or Glu, A3 is a bond, Gly or Ala, A4 is Glu or Asp, A5 is Phe, Tyr, Trp, Pgl (phenylglycine) or Nal (naphthylalanine), A6 is Glu or Asp, A7 is Glu, Asp, Pro or Ala, A8 is Ile, Leu, Val, Nle or Phe, A9 is Pro or Hyp, A10 is Glu or Asp, A11 is Glu or Asp, A12 is Phe(SO3H) or Phe(PO3H2) (preferably in the p position) or Pgl(SO3H) or Pgl(PO3H2) (preferably in the p position), A13 is a bond, Leu, Ile, Val or Ala, A14 is a bond, Gln, Asn, Glu, Asp or Cys and A15 is Cys, Cys-amide, an OH group of the alpha-carboxyl group, free or esterified with a lower alcohol with up to 4 C atoms, which can also be in the form of the carboxamide functionality whose hydrogens can optionally be replaced by alkyl groups with up to 4 C atoms, and a process for the preparation thereof are described. These peptides inhibit blood coagulation and can be used as anticoagulants.

Description

BEHRINGWERKE AKTIENGESELLSCHAFT 90/B 007 - Ma 822 Dr. Ha/Bi Peptides which inhibit blood coagulation, processes for the preparation thereof and the use thereof The present invention relates to peptides which inhibit blood coagulation, processes for the preparation thereof and the use thereof as anticoagulants.
Anticoagulants are of great therapeutic relevance in the treatment of various disorders affecting blood coagulation, such as disseminated intravascular coagulation, myocardial infarct and deep vein thrombosis. Currently employed for the therapy of these disorders are anticoagulants such as antithrombin III which is obtained from human plasma.
Recently a polypeptide from the leech (Hirudo medicinalis) composed of 65 amino acids has been tested as anticoagulant. However, the use of hirudin, as this peptide is also called, is associated with various disadvantages. One disadvantage is the problem of the low availability of this substance. Possible difficulties may also derive from the relatively high molecular weight of this peptide, which means that there is a potential risk of antibody production.
It has been possible to circumvent these disadvantages by developing low molecular weight peptides as anticoagulants, which have a high degree of homology with the Cterminal region of hirudin. Peptides of this type are described in the application EP-A 0 276 014, EP 0 333 356 and in a publication by J.M. Maraganore et al., J. Biol. Chem. 264, 8692-8698 (1989).
It is evident therefrom that a peptide of the structure Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu-OH is of particular interest. A peptide whose tyrosine (Tyr) is sulfated on the phenolic group detectably had particularly high activity. This moreover corresponds to native hirudin whose tyrosine at position 63 is sulfated.
Cyclic peptides are also of interest. These contain, in 5 addition to the sequence just mentioned, the amino acid cysteine at the C- and N-terminus, which permits cyclization in the form of a disulfide. A disulfide bridge can also be replaced by other chemical functions, preferably a connection via an amide linkage.
The chemical nature of a sulfated tyrosine is that of an ester of sulfuric acid so that the linkage between the sulfur atom and the phenolic oxygen atom can be cleaved by hydrolysis. Peptides of this type have the disadvantage of a reduced anticoagulant activity.
Thus, according to the state of the art, attempts are being made to achieve the sulfation on tyrosine by a subsequent chemical reaction. For this purpose, the unsulfated hirudin peptides are reacted with dicyclohexylcarbodiimide and sulfuric acid in organic solvents.
The sulfation can also be achieved by reaction of the tyrosine-containing peptide with sulfur trioxide triethylammonium salt in pyridine or chlorosulfonic acid.
However, these reactions have the disadvantages that side reactions can take place on phenylalanine or non-select25 ive sulfation can take place when several tyrosine residues are present. This may also lead to large losses in yield.
Hence the object of the present invention was to eliminate these disadvantages and to prepare peptides with superior physical, chemical and physiological properties.
This object has been achieved, surprisingly, by replacing the amino acid tyrosine or Tyr(SO3H) in the peptides by the amino acid Phe(S03H) or Phe(P03H2) or Pgl(SO3H) (Pgl denotes phenylglycine) or Pgl(PO3H2). In this connection, the sulfonate or phosphate group is preferably linked in the para position in the phenyl ring of the phenylalanine, but a linkage in the meta position is likewise possible.
Hence the invention relates to a peptide of the formula: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15 in which Al is hydrogen, cysteine, one or two alkyl groups with 10 1-4 carbon atoms, an acyl group with 2-10 carbon atoms, an acyl group with 2-10 carbon atoms and another carboxyl group, or a protective group customary in peptide chemistry.
A2 is a bond, Asn, Asp, Gin or Glu, 15 A3 is a bond, Gly or Ala, A4 is Glu or Asp, A5 is Phe, Tyr, Trp, Pgl (phenylglyc ine) or Nal (naphthylalanine), A6 is Glu or Asp, 20 A7 is Glu, Asp, Pro or Ala, A8 is Ile, Leu, Val, Nle or Phe, A9 is Pro or Hyp, A10 is Glu or Asp, All is Glu or Asp, 25 A12 is Phe(SO3H) or Phe(PO3H2) (preferably in the p position) or Pgl(SO3H) or Pgl(PO3H2) (preferably in the p position), A13 is a bond, Leu, Ile, Val or Ala, A14 is a bond, Gin, Asn, Glu, Asp or Cys and A15 is Cys, Cys amide, an OH group of the alpha-carboxyl group, free or esterified with a lower alcohol with up to 4 carbon atoms, which can also be in the form of a carboxamide group whose hydrogens can optionally be replaced by alkyl groups with up to 4 carbon atoms.
If Al is the amino acid cysteine, the amino group can also be acetylated.
The peptides according to the invention are synthesized by methods which are sufficiently known (G. Barany and R.B. Merrifield in The Peptides (E. Gross and I. Meienhofer, Ed.)).
The amino acids Phe(SO3H) or Pgl(SO3H) can be obtained by sulfonation of phenylalanine or phenylglycine, respectively, which are in the D or L or D,L, preferably in the L, form. A suitable sulfonating agent is sulfuric acid, which preferably also contains sulfur trioxide.
These amino sulfonic acids were provided, by methods known from C.D. Chang et al., Int. J. Peptide Protein Res. 15, 59 (1980), with a protective group on the amino group in order to be able to synthesize a peptide according to the invention. Suitable protective groups in this context are: Boc, Z, Bpoc, Ddz and, preferably, the Fmoc group.
The peptides were synthesized either by a peptide syn20 thesis method operating in solution and entailing known procedures (E. Wiinsch in Houben-Weyl, Synthese von Peptiden I (Synthesis of Peptides), G. Thieme Verlag, Stuttgart (1974)) or by solid-phase methods which are likewise known (see above), in which case Fmoc chemistry was preferably used.
The sulfonate or phosphate group was employed unprotected in the synthesis.
In the solid-phase peptide synthesis, the peptide chain was synthesized on crosslinked polystyrene (1 % divinyl30 benzene) (called resin hereinafter). The synthesis of peptides with free carboxyl groups made use of anchors based on alkoxybenzyl alcohol. Amide anchors (Int.
J. Peptide Protein Res. 34, 262-267, 1989) which produce - 5 non-alkylated peptide amides were used for peptide amides. The incorporation of the individual protected amino acids was carried out in a repetitive patterns - introduction of the Fmoc-amino acid (or amide anchor)-resin into a completely automatic peptide synthesizer - washing of the resin with DMF, dichloromethane or Nmethylpyrrolidone (about 15 ml/mg) elimination of the Fmoc group with 20 % piperidine in dimethylformamide or N-methylpyrrolidone (preferably 1x3 min and 1 x 10 min) removal of the piperidine by washing with DMF, dichloromethane, N-methylpyrrolidone or an alcohol, preferably isopropanol - coupling of the amino acid using a carbodiimide, preferably diisopropylcarbodiimide, where appropriate with the addition of HOBt, HOSu or with the use of BOP or TBTU, where appropriate with the addition of HOBt, preferably in DMF or in N-methylpyr20 rolidone.
The sidechains of the trifunctional amino acids were protected as follows: - Asp and Glu as t.-butyl ester Hyp and Tyr as t.-butyl ether - Cys as trityl ether or tert.-butyl disulfide.
In place of the Fmoc chemistry described above, these peptides can also be synthesized using the Boc strategy (J.M. Stewart and J.D. Young Solid Phase Peptide Synthesis Pierce Chemical Co., 1984, pp. 71-95) because the sulfonate group is not damaged by repetitive use of trifluoroacetic acid.
In the case of Fmoc chemistry, the peptides were eliminated from the resin using trifluoroacetic acid, preferably with the addition of a scavenger, and crystallized using ether. After purification by reversed phase chromatography, their composition was confirmed by aminoacid analysis and FAB mass spectrometry.
When cysteine-containing peptides were prepared, in the 5 case of Cys(Trt) the trityl protection was removed simultaneously with the peptide elimination as long as the elimination mixture contained an added thiol, preferably ethanedithiol.
When Cys(StBu) was employed, the S-tBu group was prefer10 ably removed after elimination of the peptide. Used for this purpose were known methods, such as, for example, treatment with tri-n-butylphosphine or dithiothreitol. Dithiothreitol deprotection was preferably used.
The cyclization via S-S bridges could be carried out by known oxidative methods.
The cysteine-containing peptide was preferably dissolved in a concentration of 0.1 to 0.001 mM in ammonium bicarbonate buffer (0.01 M) and shaken in the air for several hours. The cyclization was followed by HPLC.
Other cyclization methods, such as, for example, oxidations with iodine, for example in acetic acid, or K3[Fe(CN)6] are likewise suitable for this purpose.
A possible alternative is the preparation by a method operating in solution, in which case individual fragments of the complete peptide are initially prepared. Condensation of individual protected amino acids to give peptide segments was carried out in solvents such as DMF and tetrahydrofuran or mixtures thereof. The coupling of the amino acids was effected using carbodiimides as in the case of solid-phase synthesis. Individual segments were then combined to give the complete peptides. After elimination of the protective groups, the peptides were likewise purified and characterized.
The peptides were tested for their activity in a functional assay.
The following specific peptides were prepared, but the contents of the invention are not confined to them: Abbreviations: Asn L-asparagine Asp L-aspartic acid Cys L-cysteine Gin L-glutamine Glu L-glutamic acid Gly glycine Ala L-alanine Tyr L-tyrosine Phe phenylalanine Trp L-tryptophan Pgl L-phenylglycine Pro L-proline Ile L-isoleucine Leu L-leucine Nle norleucine Val L-valine Nal L-naphthylalanine Hyp L-hydroxyproline Boc t.-butyloxycarbonyl Z benzyloxycarbony1 Bpoc biphenylylpropyloxycarbonyl Ddz dimethyldimethoxybenzyloxycarbony1 Fmoc fluorenylmethy1oxycarbony1 DMF dimethylformamide HOBt 1-hydroxysuccinimide AC acetyl Sue succinimidyl BOP benzotriazol-1-yl-oxy-tris(dimethylamino) phosphonium hexafluorophosphate TBTU 2 (ΙΗ-benzotriazol-l-yl )-1,1,3,3-tetramethyluronium tetrafluorophosphate — 8 Osn succinimide ester TFA trifluoroacetic acid DIC di i s opropylc arbodi imide S-tBu tert.-butylthio Trt trityl FAB fast atom bombardment Examples Example 1: Preparation of Fmoc-Phe(S03H) grams of L-phenylalanine were dissolved in portions in a mixture of 17 ml of 30 % strength oleum and 20 ml of cone, sulfuric acid. The mixture was heated at 100°C for 1 hour and then poured into 200 ml of ice-water. The acid was neutralized with barium hydroxide, and the barium sulfate was filtered off. The filtrate was chromatographed on a column (Dowex 50WX2, 50-100 mesh, dimensions 230 x 32 mm) with water as eluent. Evaporation of the solvent resulted in 18.5 grams of L-parasulfophenylalanine. 7.35 grams of the amino acid were taken up in 150 ml of % strength sodium carbonate solution. To this was added, while stirring, a solution of 10 grams of Fmoc-OSu in 300 ml Of dioxane. The mixture immediately became gellike and was stirred at room temperature for 2 hours. The precipitate was filtered off and the dioxane was evapor25 ated off. The agueous solution was extracted 3 x with ether and acidified to pH 2 with 1 N hydrochloric acid.
Another impurity was extracted with ethyl acetate. The agueous phase was evaporated in a rotary evaporator and the crystalline residue was dried over RSicapent in vacuo.
Example 2: Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-OH 0.83 gram of Fmoc-Leu-resin (0.5 mmol) was made ready in a peptide synthesizer from Advanced Chemtech (Louisville, Kentucky, USA) in accordance with the manufacturer's instructions for coupling the next amino acid. FmocPhe(SO3H) (1.5 mmol) and 2.25 mmol of HOBt were dissolved in 15 ml of DMF and 15 ml of DMSO, and 1.6 mmol of DIC were added. After one hour, the mixture was added to the Leu-resin and coupling was carried out for two hours.
Synthesis was then completed by standard methods. TBTU with a 3-fold excess of amino acid was used for the coupling. The coupling time was 35 minutes in each case. The peptide-resin was treated with 27 ml of TFA, 1.5 ml of ethanedithiol and 1 g of resorcinol for one hour. The peptide solution was crystallized in ether, filtered off and dried. Crude yield 405 mg. 110 mg of this crude peptide were purified on an HPLC column (Shandon, RP-18, 250 x 20 mm) with a 0.1 TFA/acetonitrile gradient. The peptide was isolated by freeze drying (yield 48 mg). The peptide content determined after hydrolysis was 78 %.
The amino acid composition is evident from the attached diagram and was as expected.
Amino acid analysis: Phe(SO3H) 0.95 (1) 25 Asp 1.94 (2) Glu 4.18 (4) Pro 1.10 (1) Gly 1.00 (1) Ile 0.90 (1) 30 Leu 0.90 (1) Phe 0.99 (1) Testing: mg of the peptide were dissolved in 1 ml of buffer (20 mM Tris, 150 mM NaCl pH 7.5). The peptide was tested for the partial thromboplastin time (PTT) comparing with a peptide with the same sequence but with Tyr in place of Phe(S03H).
PTT test: 100 microliters of standard human plasma 100 100 2 minutes at 37' 100 microliters of buffer (see above) of kaolin/pathromtin (BEHRINGWERKE AG) ’C of CaCl2 solution reagent Result: Dilution Coagulation times in seconds Peptide of example Peptide with Tyr 1:4 147.2 105.2 1:8 111.8 80.5 15 1:16 89.2 71.0 1:32 81.5 65.0 1:64 72.8 57.7 1:128 63.0 52.8 1:256 56.3 47.3 20 1:512 52.2 44.7 1:1024 46.8 41.7 Blank (without peptide) 38.8 The amino-acid analyses and FAB mass spectra in each case agreed with the expected results. 25 The following peptides are prepared correspondingly: H-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -LeuOH H-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-GlnOH .
Ac-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe(S03H)-Leu-OH Sar-Glu-Tyr-Glu-Glu-1 le-Pro-Glu-Glu-Phe (SO3H )-1 le-OH Ac-Asn-Ala-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -LeuOH H-Asp-Trp-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-Gln-OH H-Asn-Gly-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu5 OH H-Asp-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Asp-OH Suc-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-OH Suc-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-OH Ac-Gly-Asp-Phe-Glu-Glu-Nle-Pro-Glu-Glu-Phe (SO3H) -Ile-Asn10 NH2 Ac-Gly-Asp-Tyr-Glu-Glu-Val-Pro-Glu-Glu-Phe (SO3H) -Leu-NH2 Suc-Glu-Ala-Asp-Tyr-Glu-Pro-Leu-Pro-Glu-Glu-Phe (SO3H) -LeuOH Ac-Gln-Ala-Asp-Phe-Asp-Asp-Phe-Asp-Asp-Phe (SO3H) -Ala-NH2 Ac-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe(S03H)-D-Leu-OH Ac-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-D-Phe (SO3H) -LeuGln-OH H-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Pgl (SO3H) -LeuOH Ac-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Pgl (SO3H) -Leu-OH Ac-Asp-Nal-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu-OH Cys-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -LeuCys-OH Cys-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -Leu25 Gln-Cys-OH Cys-Asn-Gly-Asp-Tyr-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO3H) -LeuCys-OH 1. A peptide of the formula I

Claims (15)

1. Patent claims: A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15 in which 5 Al is hydrogen, cysteine, one or two alkyl groups with 1-4 carbon atoms, an acyl group with 2-10 carbon atoms, an acyl group with 2-10 carbon atoms and another carboxyl group, or a protective group customary in peptide chemistry, 10 A2 is a bond, Asn, Asp, Gin or Glu, A3 is a bond, Gly or Ala, A4 is Glu or Asp, A5 is Phe, Tyr, Trp, Pgl (phenylglycine) (naphthylalanine), or Nal 15 A6 is Glu or Asp, A7 is Glu, Asp, Pro or Ala, A8 is Ile, Leu, Val, Nle or Phe, A9 is Pro or Hyp, A10 is Glu or Asp, 20 All is Glu or Asp, A12 is Phe(SO 3 H) or Phe(PO 3 H 2 ) (preferably in the p position) or Pgl(SO 3 H) or Pgl(PO 3 H 2 ) (preferably in the p position), A13 is a bond, Leu, Ile, Val or Ala, A14 is a bond, Gin, Asn, Glu, Asp or Cys and A15 is Cys, Cys amide, an OH group of the alpha-carboxyl group, free or esterified with a lower alcohol with up to 4 carbon atoms, which can also be in the form of a carboxamide group whose hydrogens can optionally be replaced by alkyl groups with up to 4 carbon atoms.
2. A peptide as claimed in claim 1, in which A12 is sulfophenylalanine in the D or L form.
3. A peptide as claimed in claim 1, in which A12 is sulfophenylglycine in the D or L form.
4. A peptide as claimed in claim 1, in which Al is hydrogen, methyl, acetyl, benzoyl or succinyl.
5. 5. A peptide as claimed in claim 1 with the structure H-Asn-Gly-Asp-Phe-Glu-Glu-Pro-Glu-Glu-Phe (SO 3 H) -Leu-OH.
6. A peptide as claimed in claim 1 with the structure H-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -LeuOH, 10 H-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe(S0 3 H)-Leu-GinOH, Ac-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -Leu-OH, Sar-Glu-Tyr-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -Ile-OH, Ac-Asn-Ala-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -Leu15 OH, H-Asp-Trp-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -Leu-Gln-OH, H-Asn-Gly-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Phe(S0 3 H) -LeuOH, H-Asp-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe(S0 3 H) -Asp-OH, 20 Sue-Asp-Phe-Glu-Glu-1 le-Pro-Glu-Glu-Phe(S0 3 H)-Leu-OH, Sue -Asp-Pgl-Glu-Glu-1 le-Pro-Glu-Glu-Phe (SO 3 H) -Leu-OH, Ac-Gly-Asp-Phe-Glu-Glu-Nle-Pro-Glu-Glu-Phe (SO 3 H) -Ile-AsnNH 2 , Ac-Gly-Asp-Tyr-Glu-Glu-Val-Pro-Glu-Glu-Phe (SO 3 H) -LeuNH 2 , 25 Suc-Glu-Ala-Asp-Tyr-Glu-Pro-Leu-Pro-Glu-Glu-Phe (SO 3 H) -LeuOH, Ac-Gln-Ala-Asp-Phe-Asp-Asp-Phe-Asp-Asp-Phe (SO 3 H) -Ala-NH 2 , Ac-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Phe (SO 3 H) -D-LeuOH, 30 Ac-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-D-Phe (SO 3 H) -LeuGln-OH, H-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Pgl(S0 3 H)-LeuOH, Ac-Asp-Pgl-Glu-Glu-Ile-Pro-Glu-Glu-Pgl (SO 3 H) -Leu-OH, or 35 Ac-Asp-Nal-Glu-Glu-!le-Pro-Glu-Glu-Phe(S0 3 H) -Leu-OH. Ί.
A process for preparing a peptide as claimed in claim 1 by solid-phase peptide synthesis or synthesis operating in solution.
8. A process for preparing a peptide as claimed in 5 _claim 1, which comprises the peptide chain being constructed on a polymeric support by means of repetitive coupling of protected amino acids or oligopeptides and being cleaved off therefrom.
9. A process for preparing a peptide as claimed in 10 claim 1, which comprises constructing the peptide chain in solution using protected amino acids or protected oligopeptides, and obtaining the peptide by eliminating the protective groups.
10. A process for preparing a peptide of the formula I, 15 which comprises protected amino acid derivatives or peptide segments being coupled together in solution or on a solid phase and obtained by elimination of the protective groups and, in the case of a solid phase, by cleavage off the support resin, it being possible to carry out 20 oxidative ring closure in the case of cysteine-containing peptides.
11. A diagnostic or therapeutic agent containing a compound as claimed in claim 1.
12. A peptide of the formula I given and defined in claim 1, substantially as hereinbefore described and exemplified.
13. A process for preparing a peptide of the formula I given and defined in claim 1, substantially as hereinbefore described and exemplified.
14. A peptide of the formula I given and defined in claim 1, whenever prepared by a process claimed in a preceding claim.
15. A diagnostic or therapeutic agent according to claim 11, substantially as hereinbefore described.
IE59791A 1990-02-22 1991-02-21 Peptides which inhibit blood coagulation processes for the preparation thereof and the use thereof IE66493B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4005591A DE4005591A1 (en) 1990-02-22 1990-02-22 THE HERBAL INHIBITING PEPTIDES, METHOD FOR THEIR PRODUCTION AND THEIR USE

Publications (2)

Publication Number Publication Date
IE910597A1 true IE910597A1 (en) 1991-08-28
IE66493B1 IE66493B1 (en) 1996-01-10

Family

ID=6400736

Family Applications (1)

Application Number Title Priority Date Filing Date
IE59791A IE66493B1 (en) 1990-02-22 1991-02-21 Peptides which inhibit blood coagulation processes for the preparation thereof and the use thereof

Country Status (11)

Country Link
EP (1) EP0443598B1 (en)
JP (1) JPH0770181A (en)
KR (1) KR910021412A (en)
AT (1) ATE122684T1 (en)
AU (1) AU640739B2 (en)
CA (1) CA2036815A1 (en)
DE (2) DE4005591A1 (en)
DK (1) DK0443598T3 (en)
ES (1) ES2073601T3 (en)
IE (1) IE66493B1 (en)
PT (1) PT96836B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4103649A1 (en) * 1991-02-07 1992-08-13 Basf Ag NEW ANTICOAGULATORY EFFECTIVE PEPTIDE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341032C (en) * 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
CA2064231A1 (en) * 1989-07-20 1991-01-21 John M. Maraganore Combinations and methods for treating or preventing thrombotic diseases
WO1991002348A1 (en) * 1989-08-07 1991-02-21 Motorola, Inc. Speech recognition using spectral line frequencies
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin

Also Published As

Publication number Publication date
ATE122684T1 (en) 1995-06-15
EP0443598A2 (en) 1991-08-28
IE66493B1 (en) 1996-01-10
AU7125591A (en) 1991-08-29
KR910021412A (en) 1991-12-20
CA2036815A1 (en) 1991-08-23
EP0443598A3 (en) 1992-01-08
EP0443598B1 (en) 1995-05-17
JPH0770181A (en) 1995-03-14
PT96836A (en) 1991-10-31
PT96836B (en) 1998-07-31
DE59105479D1 (en) 1995-06-22
AU640739B2 (en) 1993-09-02
DK0443598T3 (en) 1995-09-25
DE4005591A1 (en) 1991-09-05
ES2073601T3 (en) 1995-08-16

Similar Documents

Publication Publication Date Title
US4786684A (en) Benzylthioether-linked solid support-bound thiol compounds and method for peptide synthesis
JPS62129297A (en) Calcitonin gene related peptide derivative
US4351764A (en) Process for the selective formation of disulfide bridges in polypeptides and therapeutic compositions
US4397780A (en) Leucine22 -calcitonin
US4414149A (en) Glycine8 -D-arginine24 calcitonin
EP0315687B1 (en) (n-alpha-acyl, 8-glycine, des-19-leucine)-calcitonin
Moroder et al. Studies on cytochrome c. Part II. Synthesis of the protected heptapeptide (sequence 17–23) of Baker's yeast iso‐1‐cytochrome c
Chino et al. Generation of two isomers with the same disulfide connectivity during disulfide bond formation of human uroguanylin
AU640739B2 (en) Peptides which inhibit blood coagulation, processes for the preparation thereof and the use thereof
US4804742A (en) Amide analogs of calcitonin
Glass et al. Bidirectional solid-phase peptide synthesis. Extension of the dinitrophenylene-bridging method to cysteine-containing peptides
Wong et al. Synthesis of a fully active snake venom cardiotoxin by fragment condensation on solid polymer
US5001222A (en) Des-17-histidine-calcitonin
US4650854A (en) Amide analogs of calcitonin
US4820804A (en) Analogs of [1,7-di-alanine, des-19-leucine]calcitonin
RU2010799C1 (en) Derivatives of pentapeptides
US4451395A (en) Des-serine2 -des-tyrosine22 calcitonin
Diaz et al. A large-scale synthesis of somatostatin for clinical use by a novel alternating solution/solid-phase procedure
EP0495013B1 (en) Hexapeptides with sulphate ester groups
US4639509A (en) [16,19-Di-alanine] calcitonin
EP0370165B1 (en) Novel calcitonin derivative and salt thereof
US4388235A (en) Synthesis of peptides
YAMASHIRO et al. Synthesis and properties of human β‐endorphin‐(1–9) and its analogs
US4469632A (en) D-Arginine24 calcitonin
Byrnes et al. SYNTHESIS AND CHARACTERIZATION OF DENDROTOXIN: A POTENT POTASSIUM CHANNEL

Legal Events

Date Code Title Description
MM4A Patent lapsed